scholarly journals Mini-Review: Sarcomatoid Non-Clear Cell Renal Cancer

2017 ◽  
Vol 6 (2) ◽  
pp. 1
Author(s):  
Saikrishna Gadde ◽  
Benjamin Jones ◽  
Christopher Old
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Cell Cancer ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma ◽  
Difficult Cases ◽  
Cell Renal Cancer ◽  
Sarcomatoid Differentiation

Sarcomatoid differentiation can occur within any subdivision of renal cell carcinoma. Although the prevalence of sarcomatoid renal cell cancer has been reported to be anywhere from 1-15% of renal cancers, sarcomatoid non-clear cell renal carcinoma is actually very rare. Studies on these cancers are generally limited to tens of patients. One reason for the paucity of patients with non-clear cell sarcomatoid renal cell cancer is the aggressive nature of this disease. We present a case of sarcomatoid non-clear cell renal carcinoma and review of the treatment for these difficult cases based on the available literature.

Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib

2005 ◽  
Vol 23 (31) ◽  
pp. 7889-7896 ◽  
Author(s):  
John D. Hainsworth ◽  
Jeffrey A. Sosman ◽  
David R. Spigel ◽  
Donna L. Edwards ◽  
Cara Baughman ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Skin Rash ◽  
Renal Cell ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Targeted Agents ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma

Purpose To evaluate the efficacy and toxicity of combined treatment with two targeted agents, an antibody against vascular endothelial growth factor (bevacizumab) and an epidermal growth factor receptor tyrosine kinase inhibitor (erlotinib), in the treatment of patients with metastatic clear-cell renal carcinoma. Patients and Methods Sixty-three patients with metastatic clear-cell renal carcinoma were treated with bevacizumab 10 mg/kg intravenously every 2 weeks and erlotinib 150 mg orally daily. Patients were reevaluated after 8 weeks of treatment; patients who responded continued treatment until they experienced tumor progression. Results Fifteen (25%) of 59 assessable patients (95% CI, 16% to 37%) had objective responses to treatment, and an additional 36 patients (61%) had stable disease after 8 weeks of treatment. Only eight patients' (14%) disease had progressed at this time point. The median and 1-year progression-free survivals were 11 months and 43%, respectively. After a median follow-up of 15 months, median survival has not been reached; survival at 18 months was 60%. Treatment was generally well tolerated; only two patients discontinued treatment because of toxicity (skin rash). Grade 1/2 skin rash and diarrhea were the most frequent treatment-related toxicities. Conclusion The combination of bevacizumab and erlotinib is an effective and well-tolerated treatment for patients with advanced renal cell carcinoma. The efficacy of these two drugs in combination suggests that targeting of separate pathways critical to tumor growth and dissemination may achieve results superior to either drug as a single agent. Additional development of this and other combinations of targeted agents is warranted.

scholarly journals Treatment of hepatic cystic echinococcosis patients with clear cell renal carcinoma: a case report

2019 ◽  
Vol 14 (1) ◽  
pp. 647-650
Author(s):  
Bo Ran ◽  
Lujin Cheng ◽  
Lin Kang ◽  
Tuerganaili Aji ◽  
Tieming Jiang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Hydatid Cyst ◽  
Cell Carcinoma ◽  
Cystic Echinococcosis ◽  
Renal Cell ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Clear Cell Renal Carcinoma ◽  
Echinococcal Cyst ◽  
Cell Renal Carcinoma

AbstractHuman cystic echinococcosis is a zoonosis caused by the larval cestode Echinococcus granulosus. Clear cell renal carcinoma is the most common pathological type of renal cell carcinoma. Echinococcosis complicated with carcinoma is rarely reported. Here, we reported a female patient with echinococcal cyst of the liver accompanied with clear cell renal carcinoma. This 27-year-old woman was admitted for abdominal pain. The serological testing of hydatid cyst was positive and levels of tumor markers were within the normal range. The computed tomography and histological findings confirmed hepatic echinococcal cyst complicated with renal carcinoma of kidney. Preoperative liver function was grade A. The patient underwent pericystectomy of liver hydatid cyst and partial nephrectomy. No recurrence was found at 1 year of follow-up. Liver hydatid complicated with renal cell carcinoma is rare, which should be differentiated from liver metastasis of renal cancer. Surgical resection is the optimal treatment. This case may provide insight for the diagnosis and research on the co-occurrence of tumor and hydatid cyst.

Predictors of survival in non-metastatic renal cell cancer after surgery: A retrospective analysis

2019 ◽  
Vol 3 (2) ◽  
pp. 70-79
Author(s):  
Ines Zemni ◽  
Houyem Mansouri ◽  
Sabrine Haddad ◽  
Mohamed Ali Ayadi ◽  
Maher slimene ◽  
...  
Keyword(s):  
Renal Cell ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Cell Cancer ◽  
Disease Free Survival ◽  
Fuhrman Grade ◽  
Free Survival ◽  
Cell Renal Carcinoma ◽  
Disease Free

Aim: To investigate the prognostic significance of clinical and pathological factors of non-metastatic renal cell cancer after surgery. Patients and methods: We conducted a retrospective cohort study based on the records of patients with non-metastatic renal cancer submitted to radical or partial nephrectomy between 2000 and 2015 in Salah-Azaiez Institute. Results: Median follow-up was 38 months (interquartile range: 20–64). Five-year overall and disease-free survival were 53.8% and 43.1%. In the multivariate setting, lymph node invasion (p = 0.01), clear cell renal carcinoma subtype (p = 0.014), and tumor necrosis (p = 0.009) were the only independent statistically significant predictors of disease-free survival, while Fuhrman grade (p = 0.025), clear cell renal carcinoma subtype (p = 0.044), and TNM stage (0.041) were the only factors correlated with overall survival. Conclusion: For patients with non-metastatic renal cell carcinoma, independent predictors of disease-free survival and overall survival were clear cell renal cell carcinoma, Fuhrman grade, TNM stage, lymph node invasion, and tumor necrosis. Such information could be used to guide the intensity of follow-up and identify high-risk patients who can be targeted for adjuvant therapy trials.

scholarly journals Clear cell renal cancer metastasis in the contralateral ureter: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Julien Blanc ◽  
Beat Roth
Keyword(s):  
Cancer Metastasis ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Metastatic Spread ◽  
Caucasian Patient ◽  
Clear Cell Renal Carcinoma ◽  
Case Presentation ◽  
Cell Renal Carcinoma ◽  
Cell Renal Cancer ◽  
Established Treatment

Abstract Background Clear cell renal carcinoma is known for its propensity for metastatic spread. Common sites of metastasis are the lungs, bones, lymph nodes, liver, adrenals and brain, but all organs can be affected. Contralateral ureteral metastasis is a rare phenomenon, and only a few cases have been reported in the literature. Case presentation We present the case of a 58-year-old Caucasian patient with a single contralateral ureteral metastasis of a clear cell renal carcinoma. Conclusion Ureteral metastasis of clear cell renal carcinoma is very rare, and there is no well-established treatment. For patients with low metastatic spread/volume, the aim should be to preserve kidney function, and thus metastasectomy should be considered.

scholarly journals First report of clear cell renal carcinoma metastasizing to the ischiorectal fossa 17 years after radical nephrectomy: an additional reason for lifelong follow-up

2020 ◽  
Vol 102 (9) ◽  
pp. e1-e3
Author(s):  
A Zygomalas ◽  
DJ Papachristou ◽  
N Katsiakis ◽  
A Karatzas ◽  
T Kourelis ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Ischiorectal Fossa ◽  
Clear Cell Renal Carcinoma ◽  
First Case ◽  
Cell Renal Carcinoma ◽  
History Of

Renal cell carcinoma has a high propensity for metastatic spread. There are several case reports of metastatic renal cell carcinomas associated with rare metastatic sites, in many cases more than ten years after the initial diagnosis. We present a 60-year-old man with perianal pain and a mass in the ischiorectal space, revealed by computed tomography. The patient had a history of clear cell renal carcinoma operated on 17 years ago. A wire localization surgical excision of the ischiorectal fossa mass was performed. The pathological report revealed a metastatic clear cell renal carcinoma. To our knowledge, this is the first case of a clear cell renal carcinoma metastasizing to the ischiorectal fossa reported in the literature. We therefore recommend that any newly discovered mass in any site of a patient with a history of renal cell carcinoma should be carefully explored and biopsied.

scholarly journals Clear - cell renal carcinoma: review of literature in pediatric population / Carcinoma renal de células-claras: revisão bibliográfica na população pediátrica

2020 ◽  
Vol 65 (1) ◽  
pp. 1
Author(s):  
Fernanda Monteiro Orellana ◽  
Pablo Leonardo Traete ◽  
Victor Notari de Campos ◽  
Alan Rechamberg Ziroldo ◽  
Luis Gustavo Morato de Toledo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Pediatric Population ◽  
Renal Tumors ◽  
Clear Cell Renal Carcinoma ◽  
Pubmed Database ◽  
Cell Renal Carcinoma

ABSTRACT:Introduction: The first reports of renal tumors originated from the renal tubule epithelium date from 1855, Robin, and 1867, Waldeyer. However, at the same era, some pathologists wrong believed these tumors were originated from adrenal gland tissues due to the fat content of the tumor (hypernephroid tumor theory - origin above the kidney, 1894). The first diagnostic test for renal tumor was excretory urography. Over the years, with the emergence of ultrasonography (US), it has been replaced. Nowadays, after the US screening, all renal lesions should be evaluated, in a complementary way, with computed tomography (CT) - gold standard - in the pre-contrast, arterial, portal, nephrographic phases. This is necessary to characterize the presence of enhancement after contrast. A kidney injury that enhances more than 15 Housfield units (UH) is suspected of kidney cell cancer. There are different subtypes of renal tumors derived from various sites of the nephron. Clear cell Renal Cell Carcinoma (RCC) is one of the subtypes that originates from the renal cortex. It is a rare tumor in children. Objective: The aim of this chapter is to review de incidence, pathology, diagnosis and treatment in clear-cell renal carcinoma in pediatric population. Methods: The authors performed a literary review about clear-cell renal carcinoma in pediatric population using Pubmed Database and Campbell-Walsh Urology as source search.Keywords: Renal cell carcinoma, Tumor, Pediatrics, Kidney, Nefrectomy ResumoRESUMO:Introdução: Os primeiros relatos de tumores renais originados do epitélio do túbulo renal datam de 1855, Robin, e 1867, Waldeyer. Contudo, na mesma época, alguns patologistas acreditavam erroneamente que esses tumores provinham dos tecidos das glândulas supra-renais, devido ao teor de gordura do tumor (hypernephroid tumor theory – origem acima do rim, 1894). O primeiro teste diagnóstico para tumor renal foi a urografia excretora. Ao longo dos anos, com o surgimento da ultrassonografia, esse teste foi substituído. Atualmente, após a leitura da ultrassonografia, todas as lesões renais devem ser avaliadas, de forma complementar, com tomografia computadorizada (TC) – padrão ouro – nas fases pré-contraste, arterial, porta e nefrográfica. Isso é necessário para caracterizar a presença de melhora após contraste. Uma lesão renal que aumenta mais de 15 unidades Housfield (UH) é suspeita de câncer de células renais. Existem diferentes subtipos de tumores derivados de vários locais do néfron. O carcinoma de células renais de células claras (CCR) é um dos subtipos originários do córtex renal. É um tumor raro em crianças. Objetivo: O objetivo deste capítulo é revisar a incidência, a patologia, o diagnóstico e o tratamento do CCR na população pediátrica. Método: Os autores realizaram uma revisão literária sobre carcinoma renal de células claras em população pediátrica usando a base de dados PubMed e o livro Campbell-Walsh de Urologia como fonte de pesquisa.Palavras chave: Carcinoma de células renais, Tumor, Pediatria, Rim, Nefrectomia

scholarly journals Metastatic Clear Cell Renal Carcinoma with Benign Ultrasonographic Findings in the Thyroid Gland

2021 ◽  
Vol 6 (2) ◽  
pp. 63-66
Author(s):  
Wook Yi ◽  
Bo Hyun Kim ◽  
Jeong Mi Kim ◽  
Yong Ki Kim
Keyword(s):  
Renal Cell Carcinoma ◽  
Thyroid Gland ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Carcinoma ◽  
Clear Cell ◽  
Final Diagnosis ◽  
Needle Aspiration ◽  
Clear Cell Renal Carcinoma ◽  
Cell Renal Carcinoma

Metastasis to the thyroid gland is rare, and the incidence of thyroid metastasis is from 1.4% to 3% for all thyroid malignancies. The most common metastatic malignancy to the thyroid gland is renal cell carcinoma. Ultrasonography is useful to assess the malignancy risk of thyroid nodules, and the ultrasonographic features of metastatic renal cell carcinoma in the thyroid gland are hypoechoic solid nodules with increased vascularity. Here, we report a case of metastatic clear cell renal carcinoma with benign ultrasonographic features and fine-needle aspiration cytology in the thyroid gland. A 76-year-old woman visited our hospital for surgical management of a growing left thyroid mass. Her history comprised previous left nephrectomy for an unknown reason. Thyroid ultrasonography revealed a well-defined, isoechoic, solid mass. Left thyroidectomy was performed, and the final diagnosis was metastatic clear cell renal carcinoma of the thyroid gland.

Sign in / Sign up

Export Citation Format

Share Document